177167-05-4

Basic information

• Product Name: BUTTPARK 144\07-82
• Synonyms: BUTTPARK 144\07-82;6-BROMO-2-CHLOROMETHYL-QUINAZOLIN-4-OL;6-BroMo-2-chloroMethyl-1H-quinazolin-4-one;6-Bromo-2-(Chloromethyl)Quinazolin-4(3H)-One(WX130205)
• CAS NO: 177167-05-4
• Molecular Formula: C₉H₆BrClN₂O
• Molecular Weight: 273.51
• Mol File: 177167-05-4.mol

Chemical Properties

• Melting Point: 240-242 °C
• Boiling Point: 404.8±55.0 °C(Predicted)
• Appearance: /
• Density: 1.83±0.1 g/cm3(Predicted)
• PKA: -0.38±0.20(Predicted)
• CAS DataBase Reference: BUTTPARK 144\07-82(CAS DataBase Reference)
• NIST Chemistry Reference: BUTTPARK 144\07-82(177167-05-4)
• EPA Substance Registry System: BUTTPARK 144\07-82(177167-05-4)

Safety Data

• Hazardous Substances Data: 177167-05-4(Hazardous Substances Data)

Upstream product

• 177166-98-2 6-bromo-2-(chloromethyl)-4H-benzo[d][1,3]oxazin-4-one 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 155104-20-4 N-chloroacetyl-5-bromoanthranilic acid 
• 107-14-2 chloroacetonitrile 
• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 

Relevant articles and documents

Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition

Aurora A kinase, a member of the Aurora kinase family, is frequently overexpressed in various human cancers. In addition, Overexpression of Aurora A kinase is associated with drug resistance and poor prognosis in many cancers including breast cancer. Therefore, Aurora A kinase has been considered as an attractive anticancer target for the treatment of human cancers. Herein, A series of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives were designed, synthesized, and evaluated as Aurora A kinase inhibitors. The cell-based cytotoxicity assays showed that compound 16h was the most potent cytotoxic agent against all tested cancer cells and had a lower IC50 value than ENMD-2076 against MDA-MB-231 cells. Meanwhile, Aurora A kinase assay and Western blot analysis showed that 16h inhibited Aurora A kinase with an IC50 value of 21.94 nM and suppressed the phosphorylation of Histone H3 on Ser10 and Aurora A kinase on Thr288, which were consistent with the activation of Aurora A kinase. Accordingly, 16h caused aberrant mitotic phenotypes and obvious G2/M phase arrest in MDA-MB-231 cells and induced caspase-dependent apoptosis in MDA-MB-231 cells. These results demonstrated that 16h is a potential candidate for the development of anticancer agents targeting Aurora A kinase.

Design, Synthesis, and Anti-ToCV Activity of Novel 4(3 H)-Quinazolinone Derivatives Bearing Dithioacetal Moiety

Tomato chlorosis virus (ToCV) has caused great harm to the production of tomato worldwide. To develop efficient anti-ToCV agents, some novel 4(3H)-quinazolinone derivatives containing dithioacetal were designed and synthesized, and their anti-ToCV activities were evaluated by microscale thermophoresis (MST) using ToCV coat protein (ToCV-CP) as a new target. The results showed that some compounds had a strong binding capacity to ToCV-CP. In particular, compounds C5 and C22 have an excellent binding capacity to ToCV-CP, with binding constant values of 0.24 and 0.25 μM, respectively. Additionally, reduced ToCV-CP gene expression levels of 81.05 and 87.59% could be achieved when tomato was treated with compounds C5 and C22, respectively, which were obviously higher than the levels after ningnanmycin (NNM) treatment (43.88%) and lead compound Xiangcaoliusuobingmi (XCLSBM) treatment (63.56%). Therefore, this work indicates that 4(3H)-quinazolinone derivatives containing dithioacetal moiety can be used as novel anti-ToCV agents.

Pyrido imidazole substituted quinazolinone derivative as well as synthesis method and application thereof

The invention discloses a pyridazole substituted quinazolinone derivative, and the structural formula thereof is as follows. The invention also discloses a synthetic method thereof. The pyrido-imidazole-substituted quinazolinone derivative can induce high

6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazoline-4(3H)-one compound

The invention discloses a 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazoline-4(3H)-one compound,a preparation method and applications thereof, wherein the structural general formula (I) of the compoundis defined in the specification, R1 is hydrogen atom, morpholinomethyl, piperazinomethyl or substituted piperazinomethyl, R2 is hydrogen atom, butyl, morpholine substituted alkyl, benzyl, substitutedbenzyl, tryptamine, substituted tryptamine or N,N-dimethylamino, R3 is-C(O)R4 or-SO2R5, R4 and R5 are alkyl (C3-C6 alkyl), cycloalkyl (3-6-membered ring), alkoxy or alkyl substituted amino, and n is 1, 2, 3 or 4. The compound of the invention has inhibition activity on breast cancer, prostate cancer and human neuroblastoma.

QUINAZOLINE BASED RESPIRATORY SYNCYTIAL VIRUS INHIBITORS

Compounds of Formula (I), wherein R1, R2, R3, R4 and n are defined herein, are useful as inhibitors of RSV.

A General synthetic procedure for 2-chloromethyl-4(3H)-quinazolinone derivatives and their utilization in the preparation of novel anticancer agents with 4-anilinoquinazoline scaffolds

In our ongoing research on novel anticancer agents with 4-anilinoquinazoline scaffolds, a series of novel 2-chloromethyl-4(3H)- quinazolinones were needed as key intermediates. An improved one-step synthesis of 2-chloromethyl-4(3H)-quinazolinones utilizin

Synthesis and Reactions of 2-Chloromethyl-3,1-benzoxazin-4-ones with Amines

In continuation of our previous works on the reaction of 3,1-benzoxazin-4-ones with amines, it has been found interesting to synthesize 6-bromo and 6,8-dibromo-2-chloro-methyl-3,1-benzoxazin-4-ones IIa,b and to then study their reactions with a variety of amines.